GILEAD SCIENCES INC

Trade (domestic/foreign)

International trade and protection of intellectual property; TRIPS Waiver; compulsory licensing and other IP issues in multiple countries.

TargetedSENATE · HOUSE OF REPRESENTATIVES · U.S. Trade Representative (USTR) · Commerce, Dept of (DOC) · Health & Human Services, Dept of (HHS) · State, Dept of (DOS) · Patent & Trademark Office (PTO)

Health Issues

Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). Reauthorization of the Prescription Drug User Fee Act and related issues.

TargetedSENATE · HOUSE OF REPRESENTATIVES · White House Office · Office of the Vice President of the United States · U.S. Trade Representative (USTR) · Commerce, Dept of (DOC) · Health & Human Services, Dept of (HHS) · State, Dept of (DOS) · Centers For Disease Control & Prevention (CDC) · Food & Drug Administration (FDA) · Centers For Medicare and Medicaid Services (CMS) · Natl Institutes of Health (NIH)